Gastroesophageal Junction Cancer Latest Advances
Find the Latest Research About Gastroesophageal Junction Cancer
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1243 publications
Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026
Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026
Personalized systemic treatment of metastatic esophageal cancer
Journal: Chirurgie (Heidelberg, Germany)
Published: July 23, 2026
Clinicopathological Predictors of Pathological Response and Survival in Older Patients Undergoing Perioperative FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Journal: Medicina (Kaunas, Lithuania)
Published: July 08, 2026
Great Debate: Should Surgery Be Omitted in the Management of Gastroesophageal Junction Cancers?
Journal: Annals of surgical oncology
Published: July 06, 2026
Prevalence of Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis.
Journal: Journal of gastrointestinal cancer
Published: June 30, 2026
Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.
Journal: Current medical research and opinion
Published: June 29, 2026
Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor era.
Journal: Journal of managed care & specialty pharmacy
Published: June 24, 2026
Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report.
Journal: Journal of gastrointestinal cancer
Published: June 23, 2026
Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity?
Journal: Journal of gastrointestinal oncology
Published: June 21, 2026
Thoracoscopic Intrathoracic Double-Flap Technique for EGJC.
Journal: JSLS : Journal of the Society of Laparoendoscopic Surgeons
Published: June 12, 2026
Last Updated: 09/26/2026